A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT-Reference-Cited by-同舟云学术

A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT

Published:2009-08-17 Issue:43 Volume:28 Page:3765-3774
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Lafferty-Whyte K,Cairney C J,Will M B,Serakinci N,Daidone M -G,Zaffaroni N,Bilsland A,Keith W N

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2009238.pdf

Reference32 articles.

1. Atkinson SP, Hoare SF, Glasspool RM, Keith WN . (2005). Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 65: 7585–7590.

2. Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A et al. (2007). Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67: 9142–9149.

3. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR . (1997). Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 3: 1271–1274.

4. Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN . (2008). High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer 98: 1467–1474.

5. Cairney CJ, Keith WN . (2008). Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie 90: 13–23.

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway;ACS Pharmacology & Translational Science;2024-08-13

2. The Future of Targeted Therapy for Leiomyosarcoma;Cancers;2024-02-26

3. ALTercations at telomeres: stress, recombination and extrachromosomal affairs;Biochemical Society Transactions;2023-09-28

4. The Molecular Mechanisms and Therapeutic Prospects of Alternative Lengthening of Telomeres (ALT);Cancers;2023-03-23

5. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT;EMBO Molecular Medicine;2022-08-03